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Abstract
Background: In Australia, government-subsidised access to high-cost medicines is "targeted" to
particular sub-sets of patients under the Pharmaceutical Benefits Scheme to achieve cost-effective
use. In order to determine how this access system could be improved, the opinions of key
stakeholders on access to biological agents for rheumatoid arthritis were explored.
Methods: Thirty-six semi-structured interviews were conducted with persons from relevant
stakeholder groups. These were transcribed verbatim, and analysed thematically.
Results: Controlled access to expensive medicines was considered to be equitable and practical;
however, there was disagreement as to the method of defining the target patient populations.
Other concerns included timeliness of access, excessive bureaucracy, and the need for additional
resources to facilitate the scheme. Collaboration between stakeholders was deemed important
because it allows more equitable distribution of limited resources. The majority considered that
stakeholder consultation should have been broader. Most wanted increased transparency of the
decision-making process, ongoing and timely review of access criteria, and an increased provision
of information for patients. More structured communication between stakeholders was proposed.
Conclusion: The Pharmaceutical Benefit Scheme is adapting to meet the changing needs of
patients. Provision of subsidised access to high-cost medicines in a manner that is affordable for
individuals and society, and that is equitable and efficiently managed is challenging. The views of
stakeholders on targeted access to anti-rheumatic biological medicines in Australia acknowledged
this challenge and provided a number of suggestions for modifications. These could serve as a basis
to inform the debate on how to change the processes and policies so as to improve the scheme.
Introduction
Drug reimbursement systems grapple with the challenges
of funding innovative but costly medicines in the face of
increasing cost constraints, in part due to rapidly increas-
ing demands for access to these drugs by consumers and
prescribers. In Australia, government-subsidised access to
prescription medicines is provided through the Pharma-
ceutical Benefits Scheme (PBS). Decisions on drug sub-
sidy are based on assessment by the Pharmaceutical
Benefits Advisory Committee (PBAC), which evaluates
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incremental effectiveness and cost-effectiveness of the
medicine [1]. Criteria for access to PBS listed medicines
are based on clinical trial evidence and economic evalua-
tions.
Increasingly, there is collaboration between the PBAC, the
sponsor, and medical organisations (e.g. Australian Rheu-
matology Association) to develop access criteria. A repre-
sentative example of such a collaboration is the
consultation process that contributed to the decision to
subsidise and the criteria to access etanercept, a high-cost
biological medicine for treating rheumatoid arthritis
(RA). This process set a new paradigm for analogous PBS
decisions [2,3]. A broad definition of "high-cost medi-
cines" in Australia is medicines whose acquisition cost is
greater than A$10,000 per patient per treatment course
[4]. Although not directly involved in the consultation
process, there was considerable support and lobbying
activities by consumer representatives (namely the Arthri-
tis Foundation of Australia) for 'targeted' access to high-
cost biologicals. Access to high-cost medicines under the
PBS is tightly regulated, requiring approval by Medicare
Australia (a government body that administers the PBS)
before it can be prescribed with subsidy by a doctor. Sub-
sidised access to the anti-rheumatic biologicals is only
provided for patients who meet criteria for both starting
and continuing therapy. These criteria include both clini-
cal and laboratory based measures (Table 1) [2]. Other
biologicals subsequently subsidised by the PBS for treat-
ing RA are: infliximab, adalimumab, anakinra, and rituxi-
mab.
'Stakeholders', for the purpose of this study, were defined
as individuals or groups of people having the potential to
influence the decisions on the access arrangements, as
well as those affected by the PBS restrictions. In reviewing
the published literature, no studies apart from our own
have examined the views of stakeholders regarding this
novel approach to control subsidised access to high-cost
medicines. This study examined the perceptions and expe-
riences of stakeholders with respect to access to high-cost
medicines under Australia's PBS using, as an example, the
anti-rheumatic biologicals.
Methods
In-depth semi-structured interviews were conducted with
participants drawn from the stakeholder groups that were
involved in access to biologicals through the PBS. Based
Table 1: Access arrangements for biological agents for RA under the PBS
Authority requirements
Criteria for initiating • Severe active disease:
treatment a) elevated levels of inflammatory markers (ESR > 25 mm/hour or CRP > 15 mg/L)
b) swollen and tender joints – a total of > 20 joints, or > 4 major joints (elbow, wrist, knee, ankle, 
shoulder, hip)
• A record of rheumatoid factor positive status (this requirement was removed as of June 2005)
• Failure to achieve adequate response to a step-up sequence of treatment with conventional 
DMARDs:
a) monotherapy with methotrexate (20 mg per week)
b) a combination of methotrexate (> 7.5 mg per week) and 2 other DMARDs for at least 3 months
c) leflunomide, leflunomide with methotrexate, or cyclosporin for at least 3 months
• Evidence of intolerance or contraindication to DMARDs
• Patients required to sign a 'patient acknowledgement form'
• Treatment is approved for 16 weeks only (treatment of 22 weeks is approved for infliximab)
A patient agreement process • A Patient Acknowledgement Form to be signed by patients to acknowledge that PBS subsidised 
treatment will only continue if the predetermined response criteria are achieved at 12 weeks
Criteria for continuing treatment • Clinical outcomes are evaluated according to predetermined quantifiable criteria at 12 weeks:
a) Reduction in levels of inflammatory markers, ESR < 25 mg/hour, or CRP < 15 mg/L, or 20% from 
baseline levels
b) Reduction in the total number of joint count by 50%
'Interchangeability' (introduced 
December 2004)
• Patients approved to commence PBS subsidised biological treatment are allowed to switch to an 
alternate biological agent at any time
Restricted prescribing rights • Prescription only by specialist rheumatologists initially. Prescribing rights were extended to clinical 
immunologists with expertise in the management of RA as of February 2004
'Risk-sharing' arrangement • Annual PBS expenditure for the tumour necrosis factor inhibitors group was predicted to be up to 
A$140 million
• Expenditure above this figure to be covered by the sponsoring pharmaceutical companies (details 
not clear from public documents)
ESR = erythrocyte sedimentation rate
CRP = C-reactive protein
DMARDs = disease-modifying anti-rheumatic drugsAustralia and New Zealand Health Policy 2007, 4:26 http://www.anzhealthpolicy.com/content/4/1/26
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on our definition of "stakeholders" in the case of anti-
rheumatic biologicals, interviewees included were rheu-
matologists, patients with RA, government advisors, con-
sumer advocates, public servants, and pharmaceutical
company spokespersons. Interviewees were asked to
declare any potential conflicts of interest, that is, any pre-
vious or current advisory role with a pharmaceutical com-
pany, or in any other committees or organisations that
have a vested interest in the PBS listings.
Purposeful sampling of 'information-rich' individuals
[5,6], especially those involved in formulating the criteria,
was undertaken. This led to inclusion of additional inter-
viewees i.e. the so-called 'snowball sampling technique'
[5]. Interviews were conducted using a guide based on
findings from the first phase of the study [7] by the same
investigator (CL), a research pharmacist. The main ques-
tions put to interviewees are listed in Table 2. Each inter-
view, lasting 45–80 minutes, was recorded and
transcribed verbatim.
NVivo 2.0 software was used to manage the data and to
assist the coding for major concepts arising inductively
from the data. Three investigator independently catego-
rised these concepts thematically before meeting to reach
consensus on theme choice [8,9].
A variety of techniques was used to confirm the methodo-
logical rigour. These included verifying the meaning
ascribed to interviewees by offering them the opportunity
to review edited transcripts [9], using researcher triangula-
tion to arrive at consensus on interpretation of the data
[9], using triangulation of multiple data sources (namely,
individuals from different stakeholder groups) to counter-
balance weaknesses of one source by strengths in another
[9], searching for negative or discrepant cases to enhance
interrogation of the data, and continuing to add inter-
views until overall data saturation was achieved [10].
The study was approved by the Human Research Ethics
Committees of St Vincent's Hospital Sydney, and the Uni-
versity of New South Wales, Australia.
Results
Thirty-six interviews were conducted between 2004–2005
(Table 3). None of the government advisors, public serv-
ants, consumer representatives, or patients had held advi-
sory positions or roles on behalf of a pharmaceutical
company. Four of the eight rheumatologists had been or
were on at least one advisory committee of a pharmaceu-
tical company. Marked differences were not found in the
views of rheumatologists who had held an advisory posi-
tion with a pharmaceutical company versus those who
had not. Most rheumatologists (7 out of 8) had been in
practice for more than 10 years; the number of patients
each rheumatologist treated with biologicals under the
PBS ranged from 2 to 16. Most patients (5 out of 6) were
prescribed etanercept. One nurse was included in the
study opportunistically.
Five major themes emerged: resource rationing,  excessive
bureaucracy, partnerships and inclusive decision-making, edu-
cation, and review. All were related to the perceived fairness
of the process and were essential determinants of support
for the access criteria by stakeholders.
1. Resource rationing
Providing access to expensive medicines through a pub-
licly-funded system (the PBS) was seen by all participants
as equitable and a feasible approach. Targeting access was
supported as a necessary form of "resource rationing". The
vast majority acknowledged that there were finite
resources available for the possible range of diseases. Tar-
geting access to sub-groups of patients who most need
treatment and would gain most benefit was in keeping
with spending "for value". However, interviewees disa-
greed about how the appropriate target patient popula-
Table 2: Main interview questions
1. What are the sources of information you used before prescribing the drug, or during the course of the treatment?
2. What do you see as the primary objective of the PBS arrangements for access?
3. What do you see as the strengths and weaknesses of the access scheme?
4. Have you been involved in the consultation process in regards to developing restrictions or arrangements to access the TNF inhibitors via the 
PBS? If yes,
i. Can you briefly describe your role in the consultation process?
ii. Who else took part in the consultation process?
5. Who do you think should take part in the consultation process for formulating the arrangements or restrictions for access?
6. What is the extent of your contact with other rheumatologists, local general practitioners, administrators, consumer organization, the PBAC? 
And what were the purposes of these contacts?
7. What do you see as the role and responsibility of the prescribers? The PBAC? The industry? Arthritis Foundation?
8. Who, in your view, has responsibility in informing/'educating' the prescribers (and the public) regarding PBS restriction changes, or new complex 
PBS restrictions?
9. How important an advance do you think the consultation approach and access arrangements represent?
10. If a new and expensive drug comes along that is a significant advance for the treatment of a chronic disease, what differences would you like to 
see in the process of getting it listed and using it?Australia and New Zealand Health Policy 2007, 4:26 http://www.anzhealthpolicy.com/content/4/1/26
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tion should be defined. A government advisor recognised
the tensions between system-wide and individual needs:
"It [controlled access] is entirely defensible in terms of
a population utility concept. It's very difficult at an
individual patient level."
Some participants suggested broader, initial access. The
risk of excessive uptake of the biologicals by patients out-
side the PBS criteria was considered, by these participants,
to be limited given the other controls that were applied,
namely, risk-sharing between sponsors and government
via price-volume agreements, and the continuation rule that
limited ongoing access to those who responded to treat-
ment. All agreed that the criteria should be based on
sound clinical evidence. However, some criteria were seen
as "arbitrary" and "potentially unfair" particularly when
they were "unsupported by published literature". A rheu-
matologist gave his opinion:
"I think ... the restriction to seropositive patients is
unfortunate. Secondly, the reliance on laboratory indi-
ces is a concern ... "
The requirement for 'positive rheumatoid factor' (serop-
ositive) was removed shortly after the completion of this
study and such opinions may have been rescinded subse-
quently.
The requirement to first trial existing, less costly therapies
was considered to be reasonable. Limiting prescribing
rights to sub-specialist physicians (rheumatologists,
immunologists) was deemed safe and appropriate, given
the expense of the medicines, the severity of RA in the
affected patient population, and long-term safety con-
cerns. A patient voiced the predominant view:
"I think it's good that people have to have tried all the
other cheaper medicines, that's fair enough. Why
should the government pay for a really expensive med-
icine when methotrexate works and also, we don't
know yet what the long-term side effects will be."
While monitoring patient outcomes was supported,
patients were apprehensive that an effective treatment
might be withdrawn if one missed the threshold response
to qualify for ongoing treatment. Further, prescribers
might feel pressured to 'modulate' measurements of dis-
ease activity to benefit individual patients while, in effect,
denying treatment for others. Some interviewees sug-
gested that the continuation rule be removed, and others
proposed increased flexibility with respect to the timing of
the assessment, including less frequent assessment. A rep-
resentative quote from one rheumatologist illustrates this
view:
"I think a system that had more flexibility for the
renewal, possibly by making the reapplication less fre-
quent, or having a larger window within which the
appropriate blood test could be acquired, or allowing
so-called unacceptably high ESR [erythrocyte-sedi-
mentation-rate] or CRP [C-reactive-protein] or joint
count for a period of time, until things settle down
Table 3: Characteristics of interview participants (n = 36)
Number of participants
Age group
18–29 years 1
30–39 years 5
40–49 years 8
50–59 years 14
60 years and over 8
Sex
Male 13
Female 23
Stakeholder group
Rheumatologist 8
Patient 6
Government advisor 5
Public servant 8
Consumer representative 5
Pharmaceutical industry representative 3
Clinical nurse 1Australia and New Zealand Health Policy 2007, 4:26 http://www.anzhealthpolicy.com/content/4/1/26
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again... a little less anxiety-provoking for the patients
would be good."
However, government advisors and public servants
believed that the interpretation of joint tenderness and
swelling by clinicians and patients, being subjective,
allowed some flexibility. Further, they believed that
assessment of eligibility was flexible because applications
for subsidised treatment were assessed by pharmacists and
medical advisors from Medicare Australia, the responsible
agency. Both prescribers and patients believed that clini-
cians who see individual patients should have such discre-
tion because, as a patient put it: "people in government
aren't educated about the disease [RA]". A government
advisor voiced the opposing view about allowing flexibil-
ity with borderline cases:
"the problem with the high-cost drugs is it's very diffi-
cult to be flexible because small changes in flexibility
start to blow budgets out to massive amounts of
money and that means that the whole principle of
equity and equitable access to these things are not
obeyed. ... I don't think the uncertainty can be borne
only by Australian taxpayers."
The Patient Acknowledgement Form was seen as a contract
between the patient and the government, and reduced the
direct pressure on the individual rheumatologists. Some
rheumatologists and patients saw this agreement as
"pointless" because treatment would be discontinued
even if the patients disagreed, and it was unlikely that
patients would wish to continue if the treatment was inef-
fective. A common view of patients was: "when you're des-
perate you'll sign anything."
2. Excessive Bureaucracy
The access scheme controlled the usage and expenditure
of biologicals effectively in the first years of operation.
This was seen as a good outcome by the majority. How-
ever, there was concern by some that the use of biologics
was inappropriately low.
Most had the view that medical care had become "more
bureaucratic" as a result of the PBS processes. A rheuma-
tologist commented:
"It seems to be a very bureaucratic way of giving med-
ical care, rather than a normal doctor-patient relation-
ship... it's eliminating the ability of the doctor to show
some level of discretion..."
The majority thought the application process was admin-
istratively burdensome. Patients were anxious about coor-
dination of laboratory tests, joint assessment, application
forms, and ordering the medicine from pharmacies in
order to obtain ongoing supply. Physicians experienced
difficulties in locating documents including records of
laboratory tests and details of treatment history, some of
which depended upon other clinicians who had treated
patients previously. However, improved documentation
was seen as a good outcome overall, and an application
for access was easier for more recently diagnosed patients.
Prescribers were uneasy that there was no recompense for
the substantial additional time to undertake the tasks to
apply for access for their patients. Assistance (e.g. from
nurses) was in general unavailable as the majority of rheu-
matologists in Australia work in private practice. Where
nurses were available, considerable workload was
imposed on them. A nurse was concerned about the
impact on hospital resources:
"In a lot of places I think that nurses are doing a lot of
the work. And there's nowhere that this has been taken
into consideration with staff and issues and so on. It's
added at least eight hours a week to my workload. ...."
There was also an increase in the use of other resources. A
public servant noted that greater resources were needed to
administer this complex scheme:
"We've got pharmacists on call and they are paid more
than admin staff would be paid. We have to go
through a more intensive process in order to approve
the application because we lose more money if we
approve it wrongly."
The requirement that there be an adequate trial of conven-
tional anti-rheumatic drugs promoted re-evaluation of
previous treatments and a more comprehensive and
aggressive use of anti-rheumatic drugs. Patients were more
easily convinced to go through these steps with the 'incen-
tive' that they might access the 'new' biologicals. A rheu-
matologist voiced the predominant view:
"It's forced our rheumatologists to re-look at the treat-
ment that patients have already received ... in reassess-
ing the patient and aiming to meet the PBS criteria,
they actually get their rheumatoid arthritis under con-
trol before requiring a biological..."
The majority considered that this effect was beneficial and
potentially systematised the treatment of RA nationwide.
3. Partnerships and inclusive decision-making
There was uniform support for the stakeholder collabora-
tion and increased communication that contributed to
the decision to subsidise biologicals. However, while gov-
ernment advisors and public servants commented that the
representative rheumatologists were cooperative, theAustralia and New Zealand Health Policy 2007, 4:26 http://www.anzhealthpolicy.com/content/4/1/26
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companies felt that the representative rheumatologists
were less willing to collaborate. The consumers felt that
communication with the Rheumatology Association and
the government was insufficient. Further, some interview-
ees suggested that consultation among rheumatologists
should be wider. An industry spokesperson commented
on the negotiation skills of the representing rheumatolo-
gists:
"I don't think they [rheumatologists] had the skills,
which is built up over experience, to be able to handle
negotiations with government. People like 'gastros'
have had good experience over quite a long time with
new therapies, and oncologists and cardiologists as
well. Rheumatologists are babes in the wood when it
comes to dealing with government."
Some believed that doctors would adequately represent
the views of patients while the majority view was that
patients should have a more direct role. A common view
was that patient representatives would need to be care-
fully selected and well-informed. Interviewees had mixed
opinions about when patients should be involved in the
process, but that they should at least be involved in devel-
oping the Patient Acknowledgement Form. Some inter-
viewees believed that negotiation between the three
primary groups (PBAC, medical specialists, companies)
was sufficient and would avoid difficulties and lengthy
negotiations potentially associated with wider consulta-
tion.
An urgent need recognised by the majority was for open
discussion to engage the broader community to work out
the overarching principles of allocation and access to
medicines. A government advisor voiced the predominant
view:
"The population as a whole needs to have some
debate about where they want to spend their money,
they are the ones that are funding it ultimately..."
Greater transparency around deliberations between stake-
holders and the rationale behind the selected criteria, cur-
rently constrained by confidentiality requirements, was
considered essential to enhance understanding of the sys-
tem and to enable the PBAC to better defend its decisions
and garner broader support.
"We need greater transparency. It's [important] people
understanding the system, taking some ownership of
the system, involving them through transparency,
through education, being prepared to speak to them.
The PBAC should defend the decisions. It's all to do
with dialogue, with the partnerships. This is not a
them-and-us system, this is our system." (government
advisor)
A comment by a rheumatologist summarised the two key
elements for future processes:
"I would like to see a more collaborative and more
open approach, because I think a lot of the negotia-
tions that eventually resulted in this listing were,
whether deliberately or accidentally, shrouded in
some secrecy and I know from the PBAC perspective
there's been some talk of deliberations being made
more transparent. If we were doing this process again
and if I had the power to change something, those are
the things I would like to see: direct consumer repre-
sentation and an open and transparent process that we
could watch evolving."
4. Education
A common view of stakeholders was that the clinicians at
Medicare Australia readily assist with queries regarding
applications. However, the majority felt that better provi-
sion of information on the criteria and application proce-
dures, particularly in the early stages of implementation,
was important. In addition to avoiding confusion and
increasing efficiency, it would enhance support for the
access criteria.
Concerns were expressed about insufficient information
for patients and inadequate clinical knowledge of the bio-
logicals among health professionals in general. Clinicians
emphasised the importance of providing information on
adverse reactions, notably risks of infection. This was
potentially a difficult task because some patients feared
that treatment might be stopped if they reported infec-
tions. Most patients felt that quality-of-life outweighed
other considerations including the potential risks of treat-
ment.
The industry interviewees felt that education was a major
responsibility of industry particularly when medicines are
subject to complex criteria for access. It was agreed that
company representatives had been helpful in providing
information to clinicians. However, most interviewees
expressed a lack of faith in the companies to supply
appropriate materials for patients or the public. Concerns
were also raised about fragmented and misleading mes-
sages delivered by the media.
Enhanced provision of information on the rationale for
restricting access, how criteria were decided, and the dis-
tinction between "effectiveness" and "cost-effectiveness"
of medicines was advocated. The Patient Acknowledgement
Form  represented an opportunity to increase patient
understanding that there were responsibilities and risks toAustralia and New Zealand Health Policy 2007, 4:26 http://www.anzhealthpolicy.com/content/4/1/26
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be shared by all parties. Most thought that information
provided by the Australian Rheumatology Association
(clinical information on the medicines) and the National
Prescribing Service (information about the PBS and its
decisions) would be most trustworthy. Consumer organi-
sations were identified as having a role in disseminating
information and providing consumer support. Interview-
ees suggested that general practitioners and other health
professionals, such as pharmacists, could be more
involved in educating patients.
5. Review
Regular review of access criteria was recommended. Drug
utilisation patterns and feedback from stakeholders
should be analysed to refine the access arrangements. The
risk-sharing agreement should also be reviewed. The proc-
esses of PBAC decision-making and stakeholder consulta-
tion would also benefit from regular evaluation. A public
servant also proposed examining the administrative
expenses associated with such a scheme:
"The administration costs [of Medicare Australia] are
not a consideration for the PBAC. We need to do some
cost-benefit analysis around the cost of building the
appropriate systems [of access] and the benefit in
reduction of use [of medicines] on PBS."
Some were disappointed that a prospective, formal evalu-
ation of the access scheme had not been established. This
was partly because stakeholders could not reach consen-
sus on who should be responsible or what were appropri-
ate funding sources. Australian rheumatologists had
implemented independently a patient registry to track
patient outcomes. Some interviewees suggested that gov-
ernment and the pharmaceutical industry should fund
such a registry collaboratively. The fact that a comprehen-
sive information system enabling evaluation had not been
developed was a concern for most interviewees.
Some rheumatologists and patients considered it a weak-
ness that a review panel for contentious cases had not
been established, while others felt that, to a degree, special
consideration had occurred informally via interactions
between Medicare Australia and rheumatologists. A
patient voiced frustration about the delayed review of the
PBS criteria:
"I would like a true appeal system. I would like who-
ever's in power to try and rectify the situation quickly
and that when they put in future criteria for any med-
icine, that they are very, very careful about the crite-
ria."
Discussion
By including individuals who represented the range of
stakeholder groups with their different and potentially
competing interests, this study sought to present a well-
rounded picture of the access scheme. In-depth insights
into stakeholders' views provide a basis to inform the
broader debate on how subsidy systems for high-cost
medicines can be improved. The major consensus finding
was that while the the current access scheme for anti-rheu-
matic biologicals can be viewed as successful, stakeholder
communication and involvement needs to be increased. A
limitation of the study was that insights into some mana-
gerial perspectives were not obtained because administra-
tors who assessed patient applications for access declined
to participate due to concerns about privacy.
The innovations introduced to establish the access scheme
were considered concordant with the expectation that
government is responsible for providing access to effective
medicines while balancing the need to use public
resources wisely. Limiting access to sub-sets of patients,
where need has been established and where use was cost-
effective, was viewed as practical and equitable. The stake-
holders were supportive of the proposition that it is possi-
ble to make high-cost medicines available and affordable
for the community and individual patients. That this had
been achieved with these drugs was accepted as an impor-
tant accomplishment. However, timeliness of access to
innovative medicines via the PBS in Australia, in compar-
ison to comparable countries, was a concern. This was
partly due to the registration process which often occurred
later in Australia than in the USA or Europe. A definition
of "timeliness of access to medicines" by interviewees of
the six stakeholder groups was not actively explored in
this study; an important issue that warrants further inves-
tigation.
Criteria for access were seen to be potentially 'unfair'
when the evidence was not publicly available. For exam-
ple, the requirement for rheumatoid-factor-positive-status to
gain access was contentious at the time of the interviews.
Most published pivotal studies did not exclude rheuma-
toid-factor-negative patients or analyse them as a sub-
group. There was insufficient evidence in the public
domain to support the view that rheumatoid-factor-posi-
tive-status was a factor predicting a better response to
treatment with etanercept [11]. However, efficacy in rheu-
matoid-factor-negative patients had not been clearly
established because of the small number of such patients
in these trials [12]. This requirement for rheumatoid fac-
tor positivity has subsequently been removed. Sustaina-
bility of a subsidy system such as the PBS is dependent
upon a rigorous and consistent process of drug review and
increased transparency around the rationale underpin-
ning decisions [13]. How the PBAC arrives at its recom-Australia and New Zealand Health Policy 2007, 4:26 http://www.anzhealthpolicy.com/content/4/1/26
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mendations for PBS listing was significantly limited by the
"commercial-in-confidence" restrictions at the time of
etanercept listing. An important milestone in this respect
is that summaries of PBAC decisions have become availa-
ble publicly recently [3,14]. Increasing transparency also
increases accountability of all parties for decisions and
performance of the system. These moves towards trans-
parency were supported by the participants.
Open dialogue and declaration of potential conflicts of
interest are important to building trust [15]. Increased
communication and collaboration between stakeholders
have been crucial steps that were initiated during the
effort to subsidise the anti-rheumatic biologicals. How-
ever, the consumer participants identified a need for
increasing the voice of patients and the public in order to
enhance the quality of decisions, and acceptance of access
criteria, a position supported by the majority of partici-
pants.
Increasing bureaucratic requirements are a threat to the
acceptance and efficient running of such access systems.
The administrative burden imposed on prescribers can be
a barrier to enrolling deserving patients and a source of
increased costs [16]. Most stakeholders, with the excep-
tion of the government advisors and public servants, pro-
posed that more reliance on physicians' integrity to
comply with PBS criteria should be considered an appro-
priate approach and would benefit patients.
A significant gap in knowledge was identified by health
professionals (namely, general practitioners, pharmacists
and nurses) and the community about the PBS and the
increasing need to control access to medicines, in particu-
lar, high-cost medicines. General practitioners and phar-
macists were identified as potentially important
contributors to the success of targeted access schemes.
They have an important role to play in educating patients
about the use of medicines in chronic diseases such as RA
and the PBS system in general. Adequate provision of
information is critical to managing patient expectations
and empowering them to participate in decision-making
processes [17].
Conclusion
The limited resources must be carefully used to provide
needed, effective and safe medicines that are affordable
for the individual and society in order to achieve optimal
outcomes. Policy makers dealing with subsidised access to
high-cost medicines might focus upon: increasing stake-
holder involvement in decisions; better methods of defin-
ing target populations; improving the timeliness of access;
increasing the flexibility for clinicians to make decisions
while reducing bureaucratic red-tape; enhancing resources
to administer systems of access; and improving communi-
cation and information based on increased transparency.
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